These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38016404)

  • 1. Cross-population evaluation of cervical cancer risk prediction algorithms.
    Elvatun S; Knoors D; Nygård M; Uusküla A; Võrk A; Nygård JF
    Int J Med Inform; 2024 Jan; 181():105297. PubMed ID: 38016404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix factorization for the reconstruction of cervical cancer screening histories and prediction of future screening results.
    Langberg GSRE; Stapnes M; Nygård JF; Nygård M; Grasmair M; Naumova V
    BMC Bioinformatics; 2022 Nov; 23(Suppl 12):484. PubMed ID: 36384425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a data-driven system for personalized cervical cancer risk stratification.
    Langberg GSRE; Nygård JF; Gogineni VC; Nygård M; Grasmair M; Naumova V
    Sci Rep; 2022 Jul; 12(1):12083. PubMed ID: 35840652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving intervention design to promote cervical cancer screening among hard-to-reach women: assessing beliefs and predicting individual attendance probabilities in Bogotá, Colombia.
    Barrera Ferro D; Bayer S; Brailsford S; Smith H
    BMC Womens Health; 2022 Jun; 22(1):212. PubMed ID: 35672816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
    Della Palma P; Moresco L; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
    BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A study of cervical cancer screening algorithms].
    Zhao FH; Zhang WH; Pan QJ; Zhang X; Chen W; Liu B; Ma JF; Hu SY; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):420-4. PubMed ID: 20819481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hierarchical continuous-time inhomogeneous hidden Markov model for cancer screening with extensive followup data.
    Meng R; Soper B; Lee HK; Nygård JF; Nygård M
    Stat Methods Med Res; 2022 Dec; 31(12):2383-2399. PubMed ID: 36039541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.
    Liao W; Coupland CAC; Burchardt J; Baldwin DR; ; Gleeson FV; Hippisley-Cox J
    Lancet Respir Med; 2023 Aug; 11(8):685-697. PubMed ID: 37030308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The risk prediction models for occurrence of cervical cancer: a systematic review].
    He BJ; Chen WY; Liu LL; Zhu HY; Cheng HZ; Zhang YX; Wang SF; Zhan SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1855-1862. PubMed ID: 34814624
    [No Abstract]   [Full Text] [Related]  

  • 12. A hidden Markov model for population-level cervical cancer screening data.
    Soper BC; Nygård M; Abdulla G; Meng R; Nygård JF
    Stat Med; 2020 Nov; 39(25):3569-3590. PubMed ID: 32854166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel metric that quantifies risk stratification for evaluating diagnostic tests: The example of evaluating cervical-cancer screening tests across populations.
    Katki HA; Schiffman M
    Prev Med; 2018 May; 110():100-105. PubMed ID: 29454079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
    Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
    Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis.
    Allotey J; Snell KI; Smuk M; Hooper R; Chan CL; Ahmed A; Chappell LC; von Dadelszen P; Dodds J; Green M; Kenny L; Khalil A; Khan KS; Mol BW; Myers J; Poston L; Thilaganathan B; Staff AC; Smith GC; Ganzevoort W; Laivuori H; Odibo AO; Ramírez JA; Kingdom J; Daskalakis G; Farrar D; Baschat AA; Seed PT; Prefumo F; da Silva Costa F; Groen H; Audibert F; Masse J; Skråstad RB; Salvesen KÅ; Haavaldsen C; Nagata C; Rumbold AR; Heinonen S; Askie LM; Smits LJ; Vinter CA; Magnus PM; Eero K; Villa PM; Jenum AK; Andersen LB; Norman JE; Ohkuchi A; Eskild A; Bhattacharya S; McAuliffe FM; Galindo A; Herraiz I; Carbillon L; Klipstein-Grobusch K; Yeo S; Teede HJ; Browne JL; Moons KG; Riley RD; Thangaratinam S
    Health Technol Assess; 2020 Dec; 24(72):1-252. PubMed ID: 33336645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
    Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
    Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening.
    Harper DM; Anderson RJ; Baker E; Yu TM
    Cancer Prev Res (Phila); 2023 Jul; 16(7):393-404. PubMed ID: 37210751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis.
    Arbyn M; Simon M; de Sanjosé S; Clarke MA; Poljak M; Rezhake R; Berkhof J; Nyaga V; Gultekin M; Canfell K; Wentzensen N
    Lancet Oncol; 2022 Jul; 23(7):950-960. PubMed ID: 35709810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China.
    Pan QJ; Hu SY; Zhang X; Ci PW; Zhang WH; Guo HQ; Cao J; Zhao FH; Lytwyn A; Qiao YL
    Cancer Cytopathol; 2013 Sep; 121(9):473-82. PubMed ID: 23907807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.